Identification of Genes of Interest for Severe Forms of Preeclampsia (PRE-OMIQUES)
Identification of Genes of Interest for Severe Forms of Preeclampsia in a Cohort of Pregnant Women With a Precise Phenotype
Preeclampsia is a pregnancy complication characterized by high blood pressure associated with damage to various organs, especially the kidneys. It happens in about 1 to 5% of pregnant women and can cause serious problems for both the mother and the baby.
Several multi-omics studies have already been conducted on preeclampsia, with promising results. However, this is preliminary data that requires further studies. The molecular markers identified in this type of study could potentially be used, first of all, for the early screening of this condition, which is not yet reliably achievable. In addition, the knowledge gained from this research would help us better understand the pathophysiology of preeclampsia. Therefore, the investigators' goal is to carry out a multi-omics analysis of preeclampsia to uncover the genetic and molecular mechanisms involved in this condition.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Mme STOERKEL Johanne
- Numéro de téléphone: 03 88 12 74 55
- E-mail: johanne.stoerkel@chru-strasbourg.fr
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
Inclusion criteria for patients in the experimental group P:
- Pregnant women between 18 and 45 years old, between 24 and 41 weeks of amenorrhea (WA), with severe preeclampsia defined according to the criteria of the joint expert recommendations of the French National College of Gynecologists and Obstetricians (CNGOF) and the French Society of Anesthesia and Intensive Care (SFAR) from 2020 "Management of the patient with severe preeclampsia." These criteria are: gestational hypertension with systolic ≥ 140 mmHg and/or diastolic ≥ 90 mmHg, and proteinuria ≥ 0.3g/24h, plus at least one of the following severity criteria:
- Severe hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 110 mmHg) or uncontrolled.
- Proteinuria > 3g/24h.
- Creatinine ≥ 90 μmol/L.
- Oliguria ≤ 500 mL/24h or ≤ 25 mL/h.
- Thrombocytopenia < 100,000/mm3
- Liver enzyme elevation with AST/ALT >2x normal.
- Epigastric abdominal pain and/or persistent or severe right upper quadrant pain "like a band."
- Chest pain, shortness of breath, acute pulmonary edema.
- Neurological signs: severe headaches not responding to treatment, persistent visual or auditory disturbances, hyperactive, widespread, and polykinetic tendon reflexes.
- Patient's free and informed consent regarding the collection of maternal blood and urine.
- Consent from both legal guardians regarding the collection of cord blood, placenta samples, and newborn data.
Inclusion criteria for patients in the control group:
- Pregnant women between 18 and 45 years old and between 24 and 41 weeks of gestation, with a pregnancy without any complications
- Free and informed consent from the patient regarding the collection of maternal blood and urine
- Consent from both holders of parental authority regarding the collection of cord blood, placental fragments, and newborn data
Exclusion Criteria:
EXCLUSION CRITERIA: for all patients
- Diabetes prior to pregnancy
- Multiple pregnancy
- Long-term medication treatment (except usual pregnancy supplements)
- Smoking, alcohol, or drug use during pregnancy
- Pre-existing liver, kidney, or heart failure
- History of bariatric surgery
- Neonatal acidosis with arterial cord pH below 7.0 (rare event)
- Genetic or chromosomal abnormality of the mother and/or newborn diagnosed prenatally
- Fetal malformation diagnosed prenatally
- Refusal to participate in the study
- Person unable to consent or under protection (guardianship, curatorship)
- Minor
- Inability to participate in the entire study
Exclusion criteria for patients in the control group T: For women in the control group, any obstetric condition (apart from delivery complications).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Experimental group P
a group of 50 pregnant women with severe preeclampsia
|
|
Control group T
a control group of 50 pregnant women without any medical conditions.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Identifying genetic and molecular markers associated with severe forms of preeclampsia
Délai: At enrollment
|
Identify, from blood, urine, and placental samples, the changes in genetic and molecular signatures as well as in cell composition associated with severe forms of preeclampsia, by comparing the expression levels of the signatures and the relative abundance of different cell populations between patients with severe preeclampsia and control patients.
|
At enrollment
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 9262
- 2024-A01653-44 (Autre identifiant: ANSM)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .